Kirk E. Evoy - Concepedia

Author

Kirk E. Evoy

The University of Texas at Austin ORCID

Also Known As

Evoy, Kirk, K Evoy, K. Evoy, Kirk E Evoy, Kirk E. Evoy, Kirk Evoy

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

The University of Texas at Austin Austin College The University of Texas Health Science Center at San Antonio University Health System Massachusetts General Hospital

About

Kirk E. Evoy is an author at The University of Texas at Austin specializing in medicine, substance abuse, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	311
2	Health Sciences	6	6	273
3	Public Health	4	4	182
4	Health Policy	3	3	97
5	Epidemiology	1	1	28

Kirk E. Evoy

Publications

624

Citations

H-Index

Page 1

	Year	Citations
Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS) Kirk E. Evoy, Jordan R. Covvey, Alyssa M. Peckham, Research in Social and Administrative Pharmacy Drug SafetySubstance AbuseSubstance UseAddictionPregabalin Abuse	2018	98
Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas Kirk E. Evoy, Lucas G. Hill, Lindsey Groff, JAMA Opioid EpidemicState LegislationDrug PolicyCommunity Pharmacy ChainsTexas 32	2018	63
Prevalence and characteristics of self-reported kratom use in a representative US general population sample Jordan R. Covvey, Samantha M. Vogel, Alyssa M. Peckham, Journal of Addictive Diseases	2020	60
Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA Lucas G. Hill, Lindsey J. Loera, Kirk E. Evoy, Addiction	2020	58
Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states Lucas G. Hill, Lindsey J. Loera, Sorina B. Torrez, Drug and Alcohol Dependence Opioid EpidemicSubstance AbuseNaloxone Nasal SprayU.s. StatesMedicine	2022	53
Predictors of Gabapentin Overuse With or Without Concomitant Opioids in a Commercially Insured U.S. Population Alyssa M. Peckham, Kirk E. Evoy, Jordan R. Covvey, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2018	47
Impact of student pharmacist–led naloxone academic detailing at community pharmacies in Texas Kirk E. Evoy, Lindsey Groff, Lucas G. Hill, Journal of the American Pharmacists Association Substance AbuseCommunity PharmaciesSubstance UseAddictionClinical Pharmacy	2019	41
Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis. Amanda Kitten, Sarah A Hallowell, Stephen R. Saklad, PubMed	2018	40
Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics Kirk E. Evoy, Chengwen Teng, Victor G Encarnacion, Substance Abuse Research and Treatment	2019	30
Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample Kirk E. Evoy, Jordan R. Covvey, Alyssa M. Peckham, International Journal of Clinical Pharmacy Drug SafetySubstance AbuseNon-prescribed ObtainmentAddictionGabapentinoid Misuse	2021	28

Page 1